These data indicate that in ER+ BC there appears to be a linear link between PI3K and AKT, with sensitivity to alpelisib and capivasertib both dependent on the ability of each compound to drive modulation of FOXO3 transcription and secondary regulation of FOXM1. The gene discussed is AKT1; the disease is breast cancer.